ReviewCancers2024
Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Detection rate of [Frontiers in medicine · 2026Pooled it
- The Evolving Role of PSMA-PET/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact.Current oncology reports · 2025Pooled it
- Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry.European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Predicting the upgrading of the International Society of Urological Pathology Grade Group in nonclinically significant prostate cancer: a multicenter observational study.Asian journal of andrology · 2026Observational
- MR Virtual Cytometry for Zone-specific Prostate Cancer Characterization with Histologic and Molecular Validation.Radiology. Imaging cancer · 2026Article
- The glycobiology of prostate cancer: an update.Oncogene · 2026Review
- Intraprostatic PSMA PET/MRI parameters and clinical markers for ISUP prediction and postoperative biochemical recurrence in patients with primary prostate cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Low PSA but high-grade prostate cancer presenting as a bladder-neck mass in a young patient with refractory bladder outlet obstruction.Urology case reports · 2026Article
- PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making.Cancers · 2026Review
- Article
- Utilization of prostate-specific membrane antigen positron emission tomography in Australia following government subsidization: Trends in primary staging and biochemical recurrence.Prostate international · 2026Article
- Focusing on Prostate-Specific Membrane Antigen in Precision Diagnosis and Treatment of Prostate Cancer.Biomedicines · 2026Review
- Noninvasive preoperative risk stratification of prostate cancer via a foundational model based deep learning with PSMA PET/CT.BMC cancer · 2026Article
- Diagnostic Accuracy of PSMA-PET/CT vs. mpMRI in Primary Staging of Intermediate- and High-Risk Prostate Cancer.Medical sciences (Basel, Switzerland) · 2026Article
- Advances in prostate cancer treatment with moderate and ultra-hypofractionated radiotherapy.World journal of clinical oncology · 2025Review
- Prostate Cancer Imaging Beyond PSMA: Applications of GRPR, AR, and Amino Acid Tracers.Diagnostics (Basel, Switzerland) · 2025Review
- Review
- In Search of Ideal Solutions for Cancer Diagnosis: From Conventional Methods to Protein Biomarkers in Liquid Biopsy.Proteomes · 2025Review
- Overdiagnosis and Overtreatment in Prostate Cancer.Diseases (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past decade, prostate-specific membrane antigen positron emission tomography (PSMA-PET) has revolutionized prostate cancer (PCa) imaging, offering greater sensitivity and specificity compared to conventional imaging modalities such as CT, MRI, and bone scintigraphy. PSMA-PET is particularly valuable in staging newly diagnosed patients with intermediate- and high-risk disease, detecting biochemical recurrence, and evaluating metastatic cases. By utilizing radiotracers that accumulate specifically in PSMA-expressing cells, even small metastases can be detected, offering a detailed assessment of cancer extent and enabling more targeted diagnostic evaluations. Among the most utilized radiotracers, [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.